The FDA’s ‘plug and play’ gene-therapy guidance comes as developers increasingly pursue modular strategies for personalized medicine—aiming to support approvals across patient subsets sharing the same underlying disease framework. By setting an approval logic that can apply to different subsets, the agency is effectively creating a path for faster iteration on therapy components. For stakeholders building gene-therapy platforms—vector systems, transgene constructs, and patient-stratification approaches—this guidance changes how companies may plan evidence generation and comparability studies. It also affects how clinical development roadmaps are structured around reusable components. The near-term impact is increased regulatory clarity on the development playbook, though companies will still need to demonstrate that interchangeable elements produce consistent clinical performance and safety profiles.